[go: up one dir, main page]

TR201902057T4 - Tetrasiklin bileşikleri. - Google Patents

Tetrasiklin bileşikleri. Download PDF

Info

Publication number
TR201902057T4
TR201902057T4 TR2019/02057T TR201902057T TR201902057T4 TR 201902057 T4 TR201902057 T4 TR 201902057T4 TR 2019/02057 T TR2019/02057 T TR 2019/02057T TR 201902057 T TR201902057 T TR 201902057T TR 201902057 T4 TR201902057 T4 TR 201902057T4
Authority
TR
Turkey
Prior art keywords
structural formula
tetracycline compounds
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Application number
TR2019/02057T
Other languages
English (en)
Inventor
Xiao Xiao-Yi
b clark Roger
Katharine Hunt Diana
Sun Cuixiang
Ronn Magnus
Zhang Wu-Yan
He Minsheng
Original Assignee
Tetraphase Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetraphase Pharmaceuticals Inc filed Critical Tetraphase Pharmaceuticals Inc
Publication of TR201902057T4 publication Critical patent/TR201902057T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Mevcut buluş Yapısal Formül (I) ile temsil edilen bir bileşiğe veya bunun bir farmasötik olarak kabul edilebilir tuzuna yöneliktir. Yapısal Formül (I) için değişkenler burada tanımlanır. Ayrıca, Yapısal Formül (I)'in bileşiğini veya bunun bir farmasötik olarak kabul edilebilir tuzunu içeren bir farmasötik bileşim ve bunun terapötik kullanımı da tarif edilir.

Claims (1)

1.
TR2019/02057T 2012-08-31 2013-08-30 Tetrasiklin bileşikleri. TR201902057T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261695947P 2012-08-31 2012-08-31

Publications (1)

Publication Number Publication Date
TR201902057T4 true TR201902057T4 (tr) 2019-03-21

Family

ID=49170898

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02057T TR201902057T4 (tr) 2012-08-31 2013-08-30 Tetrasiklin bileşikleri.

Country Status (27)

Country Link
US (3) US9573895B2 (tr)
EP (2) EP3461809B1 (tr)
JP (2) JP6301335B2 (tr)
KR (2) KR102375238B1 (tr)
CN (3) CN108329312B (tr)
AU (3) AU2013308504B2 (tr)
BR (1) BR112015004523B1 (tr)
CA (1) CA2883238C (tr)
CY (1) CY1122744T1 (tr)
DK (1) DK2890673T3 (tr)
EA (2) EA031523B1 (tr)
ES (1) ES2712476T3 (tr)
HR (1) HRP20190268T1 (tr)
HU (1) HUE042600T2 (tr)
IL (2) IL237437B (tr)
LT (1) LT2890673T (tr)
ME (1) ME03329B (tr)
MX (2) MX364400B (tr)
NZ (3) NZ740051A (tr)
PL (1) PL2890673T3 (tr)
PT (1) PT2890673T (tr)
RS (1) RS58572B1 (tr)
SG (2) SG11201501516YA (tr)
SI (1) SI2890673T1 (tr)
SM (1) SMT201900096T1 (tr)
TR (1) TR201902057T4 (tr)
WO (1) WO2014036502A2 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
PL2427425T3 (pl) 2009-05-08 2017-08-31 Tetraphase Pharmaceuticals, Inc. Związki tetracyklinowe
WO2011025982A2 (en) 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
CA2883238C (en) 2012-08-31 2021-11-23 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
IL264878B (en) * 2016-08-30 2022-06-01 Tetraphase Pharmaceuticals Inc Tetracycline compounds and methods of treatment
PH12019500822B1 (en) 2016-10-19 2024-02-21 Tetraphase Pharmaceuticals Inc Crystalline forms of eravacycline
EP3829545A1 (en) 2018-07-27 2021-06-09 Sandoz Ag Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble api
CN113444070A (zh) * 2021-07-28 2021-09-28 深圳市真味生物科技有限公司 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法
CN115448849B (zh) * 2022-11-10 2023-02-03 苏州富士莱医药股份有限公司 一种2-苄氧基-3-二苄基氨基-5-氟-6-甲基苯甲酸苯酯的制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639292A (tr)
GB935384A (en) 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) * 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) * 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) * 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) * 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) * 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) * 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) * 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) * 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) * 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
ES2168254T3 (es) 1991-10-04 2002-06-16 American Cyanamid Co Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas.
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
EP0599397B1 (en) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
WO1995022529A1 (en) 1994-02-17 1995-08-24 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US20020123637A1 (en) 1998-01-23 2002-09-05 Stuart B. Levy Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
WO2000018353A2 (en) 1998-09-28 2000-04-06 The Research Foundation Of State University Of New York A novel inhibitor of cataract formation
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
WO2001098260A1 (en) 2000-06-16 2001-12-27 Trustees Of Tufts College 7-n-substituted phenyl tetracycline compounds
BRPI0112269B8 (pt) 2000-07-07 2021-05-25 Paratek Pharm Innc composto de minociclina 9-aminometila substituída, e, composição farmacêutica
JP4963771B2 (ja) 2000-07-07 2012-06-27 トラスティーズ・オブ・タフツ・カレッジ ７、８および９−置換テトラサイクリン化合物
EP2289871A1 (en) 2000-07-07 2011-03-02 Paratek Pharmaceuticals, Inc. 7-substituted tetracycline compounds
EP2301914A1 (en) 2001-03-13 2011-03-30 Paratek Pharmaceuticals, Inc. 7,9-Substituted tetracycline compounds
CA2440757A1 (en) 2001-03-14 2002-09-19 Michael Draper Substituted tetracycline compounds as synergistic antifungal agents
EP1379255A2 (en) 2001-03-14 2004-01-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
WO2002085303A2 (en) 2001-04-24 2002-10-31 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2332546A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP1474380A4 (en) 2002-01-08 2007-04-18 Paratek Pharm Innc 4-DESDIMETHYL AMINO TETRA CYCLINE COMPOUNDS
CN101307017A (zh) 2002-03-08 2008-11-19 帕拉特克药品公司 氨基-甲基取代的四环素类化合物
CA2479877C (en) * 2002-03-21 2012-08-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP1534300A4 (en) 2002-07-12 2008-04-23 Paratek Pharm Innc TETRACYCLINE COMPOUNDS SUBSTITUTED IN 3, 10, AND 12A
JP2006503898A (ja) 2002-10-24 2006-02-02 パラテック ファーマシューティカルズ， インク． マラリア治療のための置換テトラサイクリン化合物
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
AU2004259659B2 (en) 2003-07-09 2011-11-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2005082860A1 (en) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
JP5242161B2 (ja) 2004-05-21 2013-07-24 プレジデント アンド フェローズ オブ ハーバード カレッジ テトラサイクリンおよびそれらの類似物の合成
US7858601B2 (en) * 2004-10-25 2010-12-28 Paratek Pharmaceuticals, Inc. 4-substituted tetracyclines and methods of use thereof
EP2949644A3 (en) 2004-10-25 2016-04-20 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2597212A1 (en) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
CA2597870A1 (en) 2005-02-15 2006-08-24 Wyeth 9-substituted tetracyclines
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
WO2007087416A2 (en) 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
AU2007235279B2 (en) 2006-04-07 2012-12-06 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2026776A2 (en) 2006-05-15 2009-02-25 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US7763735B2 (en) 2006-10-11 2010-07-27 President And Fellows Of Harvard College Synthesis of enone intermediate
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
EP2450347B1 (en) 2006-12-21 2015-06-24 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
TWI334106B (en) 2006-12-27 2010-12-01 Icp Electronics Inc Apparatus for converting gray scale and method for the same
CA2688725A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
EP2192111A3 (en) 2007-07-06 2010-10-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
WO2009073056A1 (en) 2007-09-07 2009-06-11 Dr. Reddy's Laboratories Ltd. Novel tetracycline derivatives as antibacterial agents
WO2009128913A1 (en) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2307027A4 (en) * 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
US9073829B2 (en) 2009-04-30 2015-07-07 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
PL2427425T3 (pl) 2009-05-08 2017-08-31 Tetraphase Pharmaceuticals, Inc. Związki tetracyklinowe
US8367654B2 (en) 2009-05-08 2013-02-05 Tetraphase Pharmaceuticals, Inc. 8-AZA tetracycline compounds
US20120115819A1 (en) 2009-05-13 2012-05-10 Clark Roger B Pentacycline Compounds
WO2011025982A2 (en) 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US20120329761A1 (en) 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
AR082633A1 (es) * 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
WO2012047907A1 (en) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
CA2883238C (en) 2012-08-31 2021-11-23 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
MA40836A (fr) 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
EP3778567A1 (en) 2016-01-22 2021-02-17 Sandoz Ag Crystalline eravacycline bis-hydrochloride
IL264878B (en) 2016-08-30 2022-06-01 Tetraphase Pharmaceuticals Inc Tetracycline compounds and methods of treatment
PH12019500822B1 (en) 2016-10-19 2024-02-21 Tetraphase Pharmaceuticals Inc Crystalline forms of eravacycline

Also Published As

Publication number Publication date
PT2890673T (pt) 2019-02-19
KR20150065172A (ko) 2015-06-12
PL2890673T3 (pl) 2019-06-28
RS58572B1 (sr) 2019-05-31
IL237437A0 (en) 2015-04-30
IL237437B (en) 2019-09-26
EP2890673A2 (en) 2015-07-08
KR102375238B1 (ko) 2022-03-15
WO2014036502A8 (en) 2014-07-31
AU2017200857B2 (en) 2018-11-22
WO2014036502A3 (en) 2014-04-24
KR102295673B1 (ko) 2021-08-27
EA036088B1 (ru) 2020-09-25
JP6301335B2 (ja) 2018-03-28
CA2883238A1 (en) 2014-03-06
MX2015002657A (es) 2015-05-20
HRP20190268T1 (hr) 2019-05-03
BR112015004523B1 (pt) 2020-08-04
JP6691157B2 (ja) 2020-04-28
WO2014036502A2 (en) 2014-03-06
US9573895B2 (en) 2017-02-21
MX390763B (es) 2025-03-21
SMT201900096T1 (it) 2019-02-28
AU2016247054A1 (en) 2016-11-03
LT2890673T (lt) 2019-04-10
AU2017200857A1 (en) 2017-03-02
HUE042600T2 (hu) 2019-07-29
CY1122744T1 (el) 2021-03-12
SI2890673T1 (sl) 2019-05-31
ES2712476T3 (es) 2019-05-13
NZ705849A (en) 2018-06-29
CN104768922A (zh) 2015-07-08
JP2018118975A (ja) 2018-08-02
US20200048193A1 (en) 2020-02-13
AU2013308504A1 (en) 2015-04-02
NZ745596A (en) 2019-09-27
AU2016247054B2 (en) 2018-08-09
AU2013308504B2 (en) 2016-11-10
SG11201501516YA (en) 2015-07-30
EP2890673B1 (en) 2018-11-14
HK1211917A1 (en) 2016-06-03
KR20210107184A (ko) 2021-08-31
CN108329312B (zh) 2021-12-31
MX364400B (es) 2019-04-24
CN108329312A (zh) 2018-07-27
CN108276404A (zh) 2018-07-13
US20170305852A1 (en) 2017-10-26
BR112015004523A2 (pt) 2017-07-04
EA031523B1 (ru) 2019-01-31
ME03329B (me) 2019-10-20
CN104768922B (zh) 2018-04-03
CA2883238C (en) 2021-11-23
IL266719A (en) 2019-07-31
NZ740051A (en) 2019-09-27
US10913712B2 (en) 2021-02-09
SG10201801703RA (en) 2018-04-27
US10315992B2 (en) 2019-06-11
JP2015528468A (ja) 2015-09-28
EP3461809A1 (en) 2019-04-03
EA201590475A1 (ru) 2016-05-31
US20160107988A1 (en) 2016-04-21
EP3461809B1 (en) 2025-03-26
EA201891804A1 (ru) 2019-06-28
DK2890673T3 (en) 2019-03-18

Similar Documents

Publication Publication Date Title
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
TR201902057T4 (tr) Tetrasiklin bileşikleri.
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201290632A1 (ru) Производные бетулина
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201591195A1 (ru) Новые хинолоновые производные
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
EA201591177A1 (ru) Трициклические соединения для ингибирования канала cftr
EA201600434A1 (ru) Применение производных бензимидазолпролина
WO2011123536A8 (en) Polycyclic tetracycline compounds
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201490573A1 (ru) Соединение бензотиазолона